May 1, 2020
Executive Editor Michael Roy speaks with Collin Reiff, M.D., and
William McDonald, M.D., about their evidence-based summary of the
literature on the clinical application of psychedelic
drugs in psychiatric disorders.
- How hallucinogens were first used, and some of the key
individuals involved in the development of these drugs for medical
- What led to the worry about use of these compounds in the
1960s, and what actions did U.S. policymakers take at the time?
- How have opinions changed from the 1960s to the present?
- How the authors conducted their research [8:23]
- How the authors determined which drugs to examine [9:38]
- What findings stood out to the authors? [10:28]
- Relationships between the psychological effects and the
neurobiology of psychedelic compounds [12:59]
- How ketamine came to be used in clinical care, and what studies
have shown about its safety and effectiveness [14:18]
- An outline of psycholytic therapy and psychedelic therapy
- What is the potential for these kinds of drugs to be misused?
- Conclusions that researchers, clinicians, and other mental
health professionals should take away [21:15]
- Recommendations for further research in this area [22:20]
Be sure to let your colleagues know about the podcast, and
please rate and review it on Apple Podcasts, Google Play, Stitcher,
Spotify, or wherever you listen to it.
Subscribe to the podcast here.
Listen to other podcasts
produced by the American Psychiatric Association.
Browse articles online.
Follow the journals of APA Publishing on Twitter.
E-mail us at email@example.com
Image: detail from a 1978 painting by Flournoy Holmes, "Fire
Being" (acrylic, 36 in x 42 in). Image provided courtesy of the
artist. For this and other works, visit